Stoke Therapeutics heads into its third-quarter report with the hard work of enrolling its pivotal Dravet syndrome trial behind it. The question now is whether the regulatory groundwork laid out last quarter is holding together. The company is still pre-commercial, so the income statement will tell investors relatively little. What matters is whether management can show that the planned FDA pre-NDA meeting produced clarity on how the Phase 3 Emperor study will be judged. The market has grown impatient waiting for that answer.

The Street expects a loss of $0.88 per share, a bit narrower than the $0.93 loss posted last quarter but well wider than the $0.65 loss a year ago. That works out to roughly a 35% deterioration from last year. Revenue is projected at $8.3 million, down about 22% from $10.6 million in the year-ago period and below last quarter's $9.3 million. None of that comes from product sales, so a miss or beat of a few cents is unlikely to move the stock much. The wider year-over-year loss is the expected cost of running a fully enrolled 162-patient trial, adding new studies and preparing for a launch. Management has not offered formal financial guidance. The more useful yardstick is cash: the company framed roughly $420 million in pro forma resources as enough to carry it to a potential U.S. launch in early 2028, and spending this quarter should look consistent with that runway.

Last quarter's call marked a pivot from generating data to executing. Emperor finished enrolling ahead of its 150-patient target with zero discontinuations, against a planning assumption of 15% dropouts. That quietly improves the study's statistical power. This report should show whether that clean record has survived as more patients pass the week-28 primary endpoint visit. About 60 had reached it at the last update. Any discontinuations would not be alarming on their own, but a continued zero would reinforce the idea that the trial is well positioned.

The bigger swing factor is the FDA. Management said the pre-NDA meeting would settle how the secondary endpoints are structured, specifically whether Vineland subdomains are tested hierarchically or as a composite. It would also confirm the sequence for a rolling NDA that begins with the manufacturing module in the first quarter of 2027. A clear description of an agreed statistical plan would validate last quarter's confident tone. Several outcomes would challenge it: vague language, a delayed meeting, or questions about the slightly different dosing interval used in Phase 3 versus the open-label extension. Investors should also check that the Phase 3 readout stays anchored to the third quarter of 2027. It already slipped once from mid-2027, and a second drift would hurt credibility more than the first. Confirmation that the infant and toddler study and the adult Dravet study remain on track to start by year-end would round out the lifecycle story. So would progress in the higher-dose STK002 cohort.

The stock has not rewarded last quarter's progress. Shares are down nearly 11% since the prior report, trailing the S&P 500 by more than 12 points. At $25.68, they sit well below the 200-day moving average near $31 and closer to the post-earnings low of $22.05 than the high of $33.94. That range also sits lower than the prior quarter's trading band. Sentiment remains bearish but has softened from the prior quarter. That suggests some skeptics are waiting for evidence rather than doubling down.

That gap between operational momentum and share price is what makes this report interesting. If Stoke can report regulatory alignment, an intact timeline and spending in line with its funded-to-launch plan, the narrative of steady de-risking stays intact heading into 2027. If the FDA discussion leaves the endpoint strategy unresolved, the recent selloff may look less like an overreaction and more like an early warning.